Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233779 | 0.86 | MAPT (0.47) | TGM2HTTFOLH1SIRT2LMNA | |
| SCHEMBL2817263 | 0.84 | MAPT (0.44) | TGM2HTTSIRT2 | |
| SCHEMBL16389741 | 0.82 | TGM2 (0.54) | TGM2HTTFOLH1SIRT2LMNA | |
| SCHEMBL233928 | 0.79 | CCR6 (0.45) | ALDH1A1 | |
| SCHEMBL25771996 | 0.79 | HTT (0.56) | TGM2HTTFOLH1SIRT2LMNA | |
| Hydrochloric Acid SCHEMBL2815500 | 0.78 | CCR6 (0.44) | ALDH1A1 | |
| SCHEMBL6840808 | 0.77 | LMNA (0.61) | TGM2HTTLMNAKEAP1NFE2L2 | |
| SCHEMBL15739517 | 0.77 | LMNA (0.61) | TGM2HTTLMNAKEAP1NFE2L2 | |
| SCHEMBL11824510 | 0.76 | LMNA (0.52) | HTTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6843985 | 0.75 | TGM2 (0.55) | TGM2HTTSIRT2LMNAKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | TGM2 209/4885HTT 2619/4885FOLH1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.